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Economic Evaluation of a Rehabilitation Program
Integrating Exercise, Self-Management, and Active
Coping Strategies for Chronic Knee Pain
M. V. HURLEY,1 N. E. WALSH,2 H. L. MITCHELL,3 T. J. PIMM,4 E. WILLIAMSON,5 R. H. JONES,1
B. C. REEVES,6 P. A. DIEPPE,7 AND A. PATEL1
Objective. To conduct an economic evaluation of the Enabling Self-Management and Coping with Arthritic Knee Pain
through Exercise (ESCAPE-knee pain) program.
Methods. Alongside a clinical trial, we estimated the costs of usual primary care and participation in ESCAPE-knee pain
delivered to individuals (Indiv-rehab) or groups of 8 participants (Grp-rehab). Information on resource use and informal
care received was collected during face-to-face interviews. Cost-effectiveness and cost-utility were assessed from between-
group differences in costs, function (primary clinical outcome), and quality-adjusted life years (QALYs). Cost-effective-
ness acceptability curves were constructed to represent uncertainty around cost-effectiveness.
Results. Rehabilitation (regardless of whether Indiv-rehab or Grp-rehab) cost £224 (95% conﬁdence interval [95% CI]
£184, £262) more per person than usual primary care. The probability of rehabilitation being more cost-effective than
usual primary care was 90% if decision makers were willing to pay £1,900 for improvements in functioning. Indiv-rehab
cost £314/person and Grp-rehab £125/person. Indiv-rehab cost £189 (95% CI £168, £208) more per person than Grp-rehab.
The probability of Indiv-rehab being more cost-effective than Grp-rehab increased as willingness to pay (WTP) increased,
reaching 50% probability at WTP £5,500. The lack of differences in QALYs across the arms led to lower probabilities of
cost-effectiveness based on this outcome.
Conclusion. Provision of ESCAPE-knee pain had small cost implications, but it was more likely to be cost-effective in
improving function than usual primary care. Group rehabilitation reduces costs without compromising clinical effec-
tiveness, increasing probability of cost-effectiveness.
KEY WORDS. Economic evaluation; Rehabilitation; Knee pain.
INTRODUCTION
Chronic knee pain is a major cause of disability (1–6).
Health and social care expenditure (3,7–9) on this condi-
tion will increase as more people live longer (10), and may
exceed predictions based on actual information as patterns
of consultation change (11) and obesity and sedentary
lifestyles increase (12,13).
Knee pain is usually managed with analgesia, despite
concerns about safety (9,14–16), efﬁcacy, and direct and
indirect costs of medication (17). Functional impairment
resulting from knee pain is frequently overlooked despite
the disability this causes and its role in the etiology of
chronic ill health, e.g., diabetes, cardiovascular disease,
obesity, depression (18). Functioning can be improved
through self-management interventions (19,20) and exer-
cise (21–23). However, complex, expensive rehabilitation
programs beneﬁt few individuals. Effective and affordable
interventions are needed that can be administered to large
numbers of people.
We have demonstrated that a rehabilitation program in-
tegrating exercise, patient education, and self-management
strategies (Enabling Self-Management and Coping with Ar-
thritic Knee Pain Through Exercise [ESCAPE-knee pain])
improves functioning (24,25). However, when planning
health care for local communities, commissioners also
ISRCTN: 94658828.
Dr. Hurley’s work was supported by an Arthritis Research
Campaign Research Fellowship.
1M. V. Hurley, PhD, R. H. Jones, MD, A. Patel, PhD: King’s
College London, London, UK; 2N. E. Walsh, MSc: University
of the West of England, Bristol, UK; 3H. L. Mitchell, MSc:
DeMontfort University, Leicester, UK; 4T. J. Pimm, PhD:
Buckinghamshire Hospitals National Health Service Trust,
Aylesbury, UK; 5E. Williamson, PhD: London School of Hy-
giene and Tropical Medicine, London, UK; 6B. C. Reeves,
PhD: University of Bristol, Bristol, UK; 7P. A. Dieppe, MD:
MRC Health Services Research Collaboration, University of
Bristol, Bristol, UK.
Dr. Jones has received consultancies (less than $10,000)
from AstraZeneca.
Address correspondence to M. V. Hurley, PhD, Rehabili-
tation Research Unit, Dulwich Community Hospital, East
Dulwich Grove, London, SE22 8PT, UK. E-mail: mike.hurley
@kcl.ac.uk.
Submitted for publication October 20, 2006; accepted in
revised form March 20, 2007.
Arthritis & Rheumatism (Arthritis Care & Research)
Vol. 57, No. 7, October 15, 2007, pp 1220–1229
DOI 10.1002/art.23011
© 2007, American College of Rheumatology
ORIGINAL ARTICLE
1220
need cost and cost-effectiveness information. This report
details the economic evaluation of ESCAPE-knee pain.
PATIENTS AND METHODS
Design, setting, and participants. A pragmatic, cluster
randomized controlled trial was carried out and analyzed
in accordance with the prespeciﬁed protocol. Inclusion
and exclusion criteria, randomization, and clinical out-
comes are described elsewhere (25). Brieﬂy, participants
had to be age 50 years or older and have attended their
primary care practice reporting mild, moderate, or severe
knee pain of more than 6 months’ duration. Exclusion
criteria were as follows: lower limb arthroplasty, physio-
therapy for knee pain during the preceding 12 months,
intraarticular injections during the preceding 6 months,
unstable medical conditions, inability/unwillingness to
exercise, wheelchair bound, and inability to understand
English. The study was approved by the local ethics com-
mittee and participants gave informed consent.
Interventions. The units of randomization were pri-
mary care practices, which were allocated to 1) usual
primary care, 2) usual primary care plus the rehabilitation
program administered to individual participants (Indiv-
rehab), or 3) usual primary care plus the rehabilitation
program delivered to groups of 8 participants (Grp-rehab).
The content and format of the rehabilitation program were
similar for Indiv-rehab and Grp-rehab, and consisted of 12
supervised sessions (twice weekly for 6 weeks). For 10–15
minutes of each session, the supervising physiotherapist
facilitated a discussion on a speciﬁc topic, advising and
suggesting simple coping strategies. Then for 30–45 min-
utes, participants performed simple exercises to improve
functioning; these exercises were personalized and pro-
gressed according to each participant’s ability. (For details
of the program see www.kcl.ac.uk/gppc/escape.) We hy-
pothesized that rehabilitation (disregarding whether costs
were incurred during Indiv-rehab or Grp-rehab) would
cost more than usual primary care, and that Indiv-rehab
would cost more than Grp-rehab.
Outcomes. The a priori primary outcome was a clini-
cally meaningful improvement (15% from baseline level)
in self-reported functioning, assessed using the physical
function subscore of the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC-func) (26), 6
months after completion of rehabilitation (7.5 months after
baseline assessment when 6-week intervention or usual
primary care control period was included). Quality of life
was assessed using the EuroQoL (EQ-5D) (27). Quality-
adjusted life years (QALYs) were calculated by applying
UK general population utility weights (28) to the 5-dimen-
sional health state descriptions for each participant.
Resource use. Management of all participants’ knee
problems continued at the primary care physician’s dis-
cretion, and was documented at assessment. Data on re-
source use were collected retrospectively at baseline and
followup using the Client Services Receipt Inventory
(CSRI) (29), which was customized to ensure it was rele-
vant to individuals with knee pain. The CSRI was admin-
istered as a face-to-face clinical interview at the baseline
assessment covering the 6 months prior to baseline assess-
ment, and at the followup assessment covering the period
between baseline assessment and 6 months after comple-
tion of the rehabilitation program (7.5 months from base-
line). Data collected included use of health and voluntary
resources, use of rehabilitation facilities, patient costs
(e.g., travel, medication, over-the-counter drugs), time off
work, social security beneﬁts, and informal care. The re-
sources used during the Indiv-rehab and Grp-rehab pro-
grams were recorded separately to estimate the costs of
rehabilitation (disregarding whether costs were incurred
during Indiv-rehab or Grp-rehab).
Unit costs. Costs were calculated for each participant by
multiplying resource use data by unit costs based on na-
tional statistics (Appendix A, available at the Arthritis
Care & Research Web site at http://www.interscience.
wiley.com/jpages/0004-3591:1/suppmat/index.html). In-
formal care costs were estimated using the replacement
cost approach by applying the unit cost of a social services
home help worker.
Unit costs of rehabilitation were estimated from a health
care perspective. Because resource inputs for a session of
Indiv-rehab and Grp-rehab did not vary between sessions
or participants, unit costs for each intervention were esti-
mated as an average cost per person per session. Interven-
tion unit cost estimations (described below) were then
applied to individual-level data, according to the number
of sessions attended, to derive a total intervention cost for
each participant. Calculation of these unit costs involved
ﬁrst identifying all resource inputs normally associated
with running one session of each program (e.g., contact
and noncontact time with the therapist, capital costs, over-
head costs, exercise equipment, materials/photocopying).
Second, the cost of each of these components was esti-
mated. A research associate (hourly rate £18.78 [$30]) su-
pervised all rehabilitation sessions. Average face-to-face
contact time was 45 minutes for each Indiv-rehab session
and 60 minutes for each Grp-rehab session; these times
were adjusted for group size, then multiplied by the hourly
cost to obtain per-person face-to-face contact time costs of
£14.09 ($23) and £2.35 ($4) for Indiv-rehab and Grp-rehab
sessions, respectively. Average noncontact time (prepare
session, write up notes) associated with each person for
each session was 30 minutes for Indiv-rehab and Grp-
rehab. This was multiplied by the hourly cost to obtain
per-person non–face-to-face contact time costs of £9.39
($15). Third, the costs of all resource components were
summed to obtain a total cost per session for each inter-
vention. Finally, the total cost for Grp-rehab was divided
by the average group size (n  8) to estimate its cost per
person per session.
All costs were standardized to 2003/2004 prices, using
the UK National Health Service Executive hospital and
community health services or personal social services in-
ﬂation indices (30). Discounting costs was unnecessary
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because of the short assessment period (6 months). Costs
are presented in British pounds sterling (£) and converted
to US dollars ($) based on a 2003 purchasing power parity
(conversion rate: £1  $1.613) that equalizes the purchas-
ing power of the 2 currencies (31).
Statistical analyses. Because the CSRI was adminis-
tered by interview, missing data were minimal. However,
if use of a particular service was reported but the quantity
was not speciﬁed, within-group mean costs for that item
for participants who did have data at the same assessment
point were used to impute missing quantities. Where in-
formation about the use of a particular service was miss-
ing, we assumed that service had not been used and a zero
cost was applied. For missing EQ-5D values at 6-month
followup, values were imputed using the last value carried
forward. Values could not be imputed for missing EQ-5D
scores at baseline.
QALYs were calculated as gains since baseline. This
calculation incorporated values from a 6-week measure-
ment. Six-week and 6-month health state measurements
were assumed to represent the time since the last assess-
ment. Proportional QALY gains for these 2 time points
were summed to represent a total 6-month gain since base-
line.
Intent-to-treat analyses were conducted. Mean costs per
group were based on participant-level costs, unadjusted
for clustering. However, a cluster adjustment was included
in the examination of differences in cost between groups.
Differences were compared using linear regression with
the cluster adjustment procedure in Stata v8.2 (StataCorp,
College Station, TX). Each cost category was adjusted for
the baseline value of the same category. To allow for the
non-normal distribution commonly associated with cost
data, 1,000 nonparametric bootstrap replications were per-
formed to obtain estimates of mean differences and 95%
conﬁdence intervals (95% CIs). The primary perspective
was that of health and social care, the secondary perspec-
tive that of society. Analyses were performed using SPSS
12.0.1 (SPSS, Chicago, IL) and Stata 8.2 (StataCorp).
Cost-effectiveness analyses. The main cost-effective-
ness analyses focused on between-group differences in
total costs and WOMAC-func (the primary outcome) at
6-month followup. In addition, a cost-utility analysis was
conducted by combining cost and QALY data.
Uncertainty concerning cost-effectiveness results was
represented by cost-effectiveness acceptability curves
(CEACs) using the net beneﬁt approach (32,33). CEACs
show the probability that one intervention is cost-effective
compared with alternative(s), given a range of willingness-
to-pay values (WTP) that a health care commissioner may
be prepared to accept for improvements in outcome.
For CEACs based on WOMAC-func, we compared Indiv-
rehab with Grp-rehab, and rehabilitation with usual care;
these comparisons were made from both the health and
social care perspective and the societal perspective. To
make the cost-effectiveness analysis meaningful to health
care commissioners, WOMAC-func was examined as the
proportion of participants showing clinically meaningful
improvements, i.e., at least 15% from baseline (34). A total
of 1,000 bootstrap samples of costs and effects data were
used to generate distributions of the mean costs and effects
for each arm to deal with the dichotomous nature of the
outcome measure.
For the CEACs based on QALYs, each intervention was
compared with the alternatives simultaneously, and ana-
lyses were only conducted from a health and social care
perspective in line with the current decision-making
framework used by the UK National Institute for Health
and Clinical Excellence. CEACs based on QALYs were
based on observed data. Both sets of CEACs were con-
structed using Excel (Microsoft, Redmond, WA) program
macros created by Elizabeth Fenwick (University of
York, UK).
Sensitivity analyses. Two sets of sensitivity analyses
were performed. First, we tested the effect of alternative
assumptions for the calculation of unit costs of rehabilita-
tion. Second, we tested the impact of alternative assump-
tions for the calculation of total health/social care costs
and total societal costs. We examined rehabilitation unit
costs under 6 alternative assumptions: supervision by a
junior therapist; reducing groups to 6 participants; increas-
ing groups to 10 participants; widening the cost difference
between the interventions by 50%; narrowing the cost
difference by 50%; taking a societal perspective that in-
cludes participant’s travel expenses, travel time to and
from, and participation in rehabilitation sessions.
For the examination of total costs, sensitivity analyses
were performed to examine alternative assumptions con-
cerning medications and informal care. There were no data
on the duration of medication use, so we assumed that all
reported medications were taken for the full period of
assessment. Because this may have overestimated medica-
tion costs, costs were reestimated assuming medications
were taken for half the assessment period (i.e., medication
costs reduced by 50%). The impact of this was tested in
the economic evaluation from the health/social care per-
spective (sensitivity analysis 1) and from the societal per-
spective (sensitivity analysis 2). Participants also had dif-
ﬁculty estimating the duration of informal care inputs and,
speciﬁcally, identifying the inputs necessitated by having
knee pain, so we excluded these from total societal costs
(sensitivity analysis 3).
RESULTS
Participant characteristics. A total of 418 individuals
(294 women) were recruited. Baseline anthropometric,
clinical, and sociodemographic characteristics were bal-
anced across trial arms; baseline mean age was 66 years
(range 50–91 years), mean height 1.64 meters (range 1.30–
1.97), body mass 81 kg (range 47–139), body mass index
30 kg/m2 (range 18–51), WOMAC-func 27.2 points (95%
CI 25.7, 28.6), and median duration of symptoms was 6
years (interquartile range 3–12). The majority of partici-
pants received some state beneﬁts, predominantly a pen-
sion. There were some between-group imbalances in re-
ceipt of social security beneﬁts at baseline (usual care: 118
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[84%] of 140; Indiv-rehab: 108 [74%] of 146; Grp-rehab:
120 [91%] of 132). At 6-month followup, economic data
were available for 338 (81%) participants and completion
rates were balanced between trial arms (usual care: 110
[79%] of 140; Indiv-rehab: 121 [83%] of 146; Grp-rehab:
107 [81%] of 132).
From the health/social care (although not societal) per-
spective, participants in the usual care arm who remained
in the study at the 6-month assessment had lower total
baseline costs and higher (better) baseline utility values
than participants who withdrew. Because these differ-
ences were not present in the intervention arms, the data
of usual care participants remaining in the study were
biased toward participants with better quality of life
and/or lower costs, causing the cost-effectiveness of reha-
bilitation to be underestimated.
Outcome results. At baseline there were no differences
between the groups in costs or utilities (Table 1). There
were some changes in costs and QALYs at the 6-month
assessment, but no overall differences between any of the
trial arms (Table 2). WOMAC-func improved in partici-
pants in Indiv-rehab and Grp-rehab, and the proportion of
participants with clinically meaningful improvement in
functioning was greater following rehabilitation than
usual primary care (121 of 226 versus 47 of 113, respec-
tively; 2  4.301, P  0.038) (Table 2).
Used resources. Resource use was low, with outpatient
and general practitioner visits the most commonly used
services. Mean visits among users of general practitioner
services were 2.6 for usual care, 1.7 for Indiv-rehab, and
1.9 for Grp-rehab. Mean visits among users of outpatient
services were 2.3 for usual care, 1.3 for Indiv-rehab, and
2.2 for Grp-rehab. Although approximately two-thirds of
participants received some level of informal care, it was at
relatively low levels (Table 3).
Rehabilitation costs. Mean costs. Usual care incurred
no rehabilitation costs. Indiv-rehab cost £30.40 ($49) per
session per person (Table 4). Accounting for attendance
rates, mean costs for Indiv-rehab were £314 ($507) per
person (Tables 2 and 4). Grp-rehab cost £14.33 ($23) per
session per person (a total cost of £114.64 [$185] per ses-
sion based on an average group size of 8 participants)
(Table 4). Mean cost of Grp-rehab was £125 ($202) per
person (Tables 2 and 4).
Differences in mean costs. Participation in rehabilita-
tion cost £224 (95% CI £184, £262 [$361; 95% CI $297,
$423]) more than usual care, with differences of £171–
£359 ($276–$579) in the alternative scenarios (Tables 2
and 4). Indiv-rehab cost £189 (95% CI £168, £208 [$305;
95% CI $271, $336]) more per person than Grp-rehab, and
was more expensive than Grp-rehab under all alternative
unit cost assumptions with differences of £128–£344
($207–$555) (Tables 2 and 4).
Total costs. There were no differences in total costs
between Indiv-rehab and Grp-rehab (Table 2). Although
rehabilitation did not have signiﬁcantly greater costs than
usual care from a health/social care perspective, it cost
£584 more from a societal perspective and based on 2
sensitivity analysis scenarios (Table 2).
Cost-effectiveness. Only participants with both cost and
relevant outcome data were included in the cost-effective-
ness analyses. For the WOMAC-based analyses from both
perspectives, the sample sizes were as follows: 110 (79%)
of 140 in usual care, 118 (81%) of 146 in Indiv-rehab, and
107 (81%) of 132 in Grp-rehab. For the QALY-based ana-
lyses, the sample sizes were 109 (78%) of 140 in usual
care, 121 (83%) of 146 in Indiv-rehab, and 106 (80%) of
132 in Grp-rehab.
If decision makers were unwilling to pay anything for an
increased proportion of individuals with improved func-
tioning, the probability that rehabilitation would be cost-
effective compared with usual care was 9% (Figure 1). If
health care commissioners were willing to pay £800
($1,291) for rehabilitation, there was 50% probability that
supplementing usual primary care with rehabilitation was
more cost-effective than usual primary care alone. This
increased to 90% at WTP values £1,900 ($3,065)
(Figure 1).
Compared with Grp-rehab, Indiv-rehab had higher costs
but only marginally better outcomes. If decision makers
were unwilling to pay anything for an increase in the
proportion of individuals improving their functioning,
there was almost zero probability Indiv-rehab would be
more cost-effective than Grp-rehab (Figure 1). The proba-
bility of Indiv-rehab being more cost-effective than Grp-
rehab increased as commissioners’ WTP increased, reach-
ing 50% probability at WTP values £6,000 ($9,678).
Because there was very little difference in QALYs across
the arms (Table 2), CEACs based on this outcome measure
showed relatively low probabilities of cost-effectiveness
for both Indiv-rehab and Grp-rehab (Figure 2). It was not
until threshold values were £19,200 that either Indiv-
rehab or Grp-rehab showed higher probabilities of cost-
effectiveness than usual care. At this threshold and above,
the probability that Indiv-rehab would be cost-effective
compared with Grp-rehab and usual care exceeded prob-
abilities of cost-effectiveness for the other 2 treatment
strategies. However, the probability did not exceed 38% in
the range of thresholds examined.
DISCUSSION
This is the ﬁrst study evaluating the costs and cost-effec-
tiveness of an integrated exercise and self-management
rehabilitation program designed to improve functioning in
persons with chronic knee pain. Rehabilitation had cost
implications, but at modest levels of investment was more
likely to be cost-effective than usual primary care: invest-
ing £1,900 (or more) provided a 90% (or greater) chance of
rehabilitation being more cost-effective than usual primary
care. Administering ESCAPE-knee pain to small groups of
individuals reduced its costs without compromising clin-
ical effectiveness, increasing the probability of cost-effec-
tiveness.
The strengths of this trial and intervention are its rigour,
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clinical relevance, and generalizability (35). Performing
prospective interview-based economic evaluation along-
side the clinical trial minimized missing data. Construct-
ing CEACs is more informative than incremental cost-
effectiveness ratios because they indicate the uncertainty
associated with the ﬁndings in the absence of knowledge
of how much health care commissioners would be willing
to pay for meaningful improvements in functioning.
Inaccurate or biased recall due to memory and cognitive
impairments is a concern in elderly individuals and may
have affected the results. However, none of our partici-
pants had overt memory problems, and all were light users
of health care services, had a slowly progressive condition,
and lived independently, therefore we have no reason to
believe that short-term recall of resource utilization was
very inaccurate or biased toward over- or underestimation
of resource use. Like many population-based economic
evaluations with a broad perspective, it was not possible to
validate self-reported resource use against all relevant ser-
vice provider records. There is no better alternative; med-
ical records are reasonably valid for conditions requiring
medical diagnosis and monitoring (e.g., diabetes, hyper-
tension) but are less valid for conditions that have impor-
tant effects on individuals but do not require continued
supervision, i.e., chronic knee pain (36).
Assessment of the amount of informal care individuals
receive is problematic but important (37). Participants
found it difﬁcult to estimate informal care in terms of time.
Frequently what we deﬁned as informal care (housework,
shopping, gardening, emotional support) were activities
that partners, family, and friends normally performed as
part of a relationship that participants played down. Some
may have been reluctant to admit needing and accepting
help. Many coped by adapting their environment and ac-
tivities (showering rather than bathing) with minimal
help. Many ignored nonessential tasks (e.g., decorating)
and refrained from or reduced participation in social ac-
tivities. This might underestimate the amount of informal
care needed.
Although the CSRI asked about impacts related to knee
pain, this is difﬁcult to disentangle from the impact of
other comorbidities common in elderly persons. Conse-
quently, the impact of knee pain may have been overstated
inadvertently. Conversely, because knee pain is a major
Table 3. Number of participants and average weekly duration of informal care inputs at
6-month followup*
Usual primary care Indiv-rehab Grp-rehab
Personal care 0.12  0.5 0.21  1.1 0.16  1.4
Home maintenance 0.20  0.5 0.24  0.5 0.26  0.5
Housework/laundry 0.94  1.9 0.84  1.7 0.68  1.9
Providing transport 0.25  0.7 0.23  0.7 0.36  1.0
Preparing meals 0.44  2.3 0.26  1.2 0.23  1.4
Gardening 0.44  0.9 0.38  0.8 0.34  0.7
Shopping 0.80  1.2 0.77  1.0 0.65  0.9
Total hours per week 3.2  5.2 2.9  4.3 2.8  5.1
Number of participants who received
any care (%)
65 (59) 66 (55) 67 (63)
* Values are the mean  SD unless otherwise indicated. See Table 1 for deﬁnitions.
Table 4. Unit costs of intervention, mean  SD intervention costs, and mean differences in costs (95% CI)*
Scenario
Rehabilitation,
mean  SD
cost†
Rehabilitation
vs usual
care,
mean
difference
(95% CI)‡
Indiv-rehab Grp-rehab
Indiv-rehab
vs Grp-rehab,
mean difference
(95% CI)‡
Unit
cost§
Mean  SD
cost†
Unit
cost§
Mean  SD
cost†
Base case 224  131 224 (184, 262) 30.40 314  111 14.33 125  61 189 (168, 208)
Junior supervisor 171  101 171 (140, 201) 23.21 241  85 10.74 95  46 146 (130, 160)
Smaller groups 229  129 229 (190, 265) 30.40 314  111 15.39 134  66 180 (159, 199)
Larger groups 222  133 222 (181, 261) 30.40 314  111 13.69 120  59 194 (174, 212)
Wider cost difference 306  214 306 (233, 376) 45.60 470  166 14.33 125  61 344 (316, 369)
Narrower cost
differences
253  120 253 (224, 280) 30.40 314  111 21.50 187  92 128 (103, 151)
Societal perspective 359  177 359 (313, 400) 44.19 455  161 29.26 253  125 203 (168, 235)
* Usual primary care had no rehabilitation costs. Conversion rate to US dollars at 2003 purchasing power parity: £1  $1.613. A ﬁxed total average
cost of £3.70 per-person for materials is excluded from the unit cost estimates but was included in calculation of individual-level costs. See Table 1
for deﬁnitions.
† Mean costs per group are based on individual-level means, unadjusted for clusters.
‡ Cluster-adjusted mean differences and conﬁdence intervals, obtained from 1,000 bootstrap replications.
§ Unit cost per session per person.
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determinant of functional limitation and functional limi-
tation is a risk factor for chronic ill health, the indirect
health care costs for chronic conditions due to functional
limitations caused by knee pain may be underestimated.
Because most participants were retired, lost productiv-
ity and social welfare beneﬁts were small. Although all the
participants reported chronic knee pain, health care costs
were low, mostly repeat medication. A large proportion of
individuals were taking over-the-counter remedies (e.g.,
ﬁsh oil, glucosamine), but few were receiving therapies
often sought for chronic pain (e.g., acupuncture, private
therapies). Individuals accepted and coped with function-
ing limitations by decreasing or altering their activities.
This enabled them to maximize their independence and
minimize the burden on others. Assistance was most fre-
quently necessary for essential arduous tasks (e.g., house-
work, shopping).
Overall, health professionals provide, and people seem
to expect and accept, a low level of care for chronic knee
pain. Chronic knee pain is regarded as a benign, inevitable
consequence of aging, for which little can be done beyond
prolonged medication, regardless of its costs (17) and risks
(9,14–16). However, because of the prevalence of knee
pain, health and social care expenditure is very great
(3,7–9) and likely to escalate as the working life extends
(increasing lost productivity, earnings, and social security
payments), the population ages, and consultations for
musculoskeletal disorders increase (11).
Usual primary care was the cheapest option but least
cost-effective. Supplementing this with rehabilitation in-
curred extra costs, but improved functioning. Group reha-
bilitation achieved comparable improvement in function-
ing at half the cost of individual rehabilitation, and
therefore was most cost-effective. This ﬁnding could be
used to justify withdrawing provision of individual ther-
apy. However, because individual sessions can be ar-
ranged at convenient times and missed sessions can be
re-arranged, removing this ﬂexible management option
might deny some people (the employed) effective treat-
ment. It may be preferable to retain this management op-
tion but reduce its costs and maximize efﬁciency by ﬁnd-
ing the optimal number of individual sessions without
compromising effectiveness.
We found little difference in QALYs between the arms.
ESCAPE-knee pain was a brief intervention designed to
improve functioning and be deliverable to many individ-
uals. It was not expected or designed to enable individuals
to function normally, completely alleviate pain, or sub-
stantially affect all factors that contribute to quality of life
Figure 1. Cost-effectiveness acceptability curves: probability
(given as percentage) that 1) rehabilitation (individual or group) is
cost-effective compared with usual primary care and 2) Indiv-
rehab is cost-effective compared with Grp-rehab, for a range of
values of health care commissioners’ willingness to pay for an
increase in the proportion of participants improving in Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC-func) by 15% at 6 months, from a health/social care
perspective. Rehabilitation  costs of individual and group reha-
bilitation programs combined; Indiv-rehab  rehabilitation pro-
gram delivered to individual participants; Grp-rehab  rehabili-
tation program delivered to groups of 8 participants; £  English
pounds sterling. Conversion rate to US dollars at 2003 purchasing
power parity: £1  $1.613.
Figure 2. Cost-effectiveness acceptability curves: probability that each treatment strategy is
cost-effective compared with the other 2, for a range of values of decision makers’ willing-
ness to pay for an additional quality-adjusted life year (QALY), from a health/social care
perspective at 6 months. Indiv-rehab  rehabilitation program delivered to individual
participants; Grp-rehab  rehabilitation program delivered to groups of 8 participants; £ 
English pounds sterling. Conversion rate to US dollars at 2003 purchasing power parity:
£1  $1.613.
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in an elderly, inner-city population (e.g., comorbidity,
family and social issues, anxiety, depression, socioeco-
nomic situation). Therefore, quality of life will remain
compromised. Moreover, the EQ-5D may be insensitive to
quality-of-life change in this patient group (38,39) and the
trial was not powered to detect meaningful change in this
outcome.
Although intervention costs could be reduced by using
junior therapists and/or larger groups, safety issues might
necessitate additional personal support, which could ne-
gate potential savings. We considered the health and social
care perspective to be the most appropriate to health com-
missioners considering productivity, because lost earn-
ings, sickness beneﬁt, and travel time are not major issues
in this retired patient population. Including these issues in
a societal perspective increased the costs in all the trial
arms, but the broad inferences from the study remain
unaltered.
This is the ﬁrst study integrating exercise and self-man-
agement for persons with chronic knee pain. There is
evidence that self-management is cost-effective for chronic
knee pain (40,41). There is less evaluation of the costs of
exercise, but recent studies of similar patient populations
demonstrated that prolonged exercise regimens resulted in
beneﬁts immediately following completion (42,43) and
were cost-effective (44–46). The important differences in
this study are that the improved functioning attained dur-
ing ESCAPE-knee pain was sustained for 6 months, the
number needed to treat was smaller (better) (43,45), and
the intervention was less costly (44,45).
Interventions for chronic pain conditions will beneﬁt
few individuals if they require participation in complex,
prolonged interventions that are impractical and too ex-
pensive to implement widely. As more individuals live
and work longer with chronic ill health, safe, affordable
interventions will be needed to maximize functioning,
independence, and efﬁcient use of health and societal
resources. ESCAPE-knee pain was designed to be a brief,
affordable, and cost-effective intervention to improve
functioning for many people. We have previously shown
it to be safe and effective (24,25). This economic evalua-
tion demonstrates that ESCAPE-knee pain is cost-effective
if value is placed on meaningful improvements in func-
tioning.
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